NCT06495541View on ClinicalTrials.gov

The Real World Study of Pyrotinib in the Treatment of Advanced Breast Cancer With HER2 Positive

NANot yet recruitingINTERVENTIONAL

Enrollment

500

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

July 30, 2026

Study Completion Date

July 30, 2028

Conditions

Breast CancerRWSPyrotinib

Interventions

DRUG

Pyrotinib

Administration method: Pyrrolitinib standard dose: 400 mg once a day, oral administration within 30 minutes after breakfast, continuous administration for 21 days per cycle. The dosage can be determined by the doctor according to the actual situation Make adjustments. Other medications: The doctor selects the medication plan based on the actual situation.

All Listed Sponsors

lead

Tianjin Medical University Cancer Institute and Hospital

OTHER

NCT06495541 - The Real World Study of Pyrotinib in the Treatment of Advanced Breast Cancer With HER2 Positive | Biotech Hunter | Biotech Hunter